CONCLUSIONS
Compared with resuspended NPH insulin, lack of resuspension profoundly alters
PK/PD and may importantly contribute to day-to-day glycemic variability of type 1
diabetes. Because of their more physiological pharmacokinetics/pharmacodynamics (PK/PD) (1) at present, the long-acting insulin analogs glargine and detemir and the
more recent basal insulin degludec (2) [along with glargine U300 soon to come
(3)] have largely replaced NPH insulin in the treatment of type 1 diabetes mellitus
(T1DM). However,NPHremains a popular basal insulin in type 2 diabetes mellitus
(T2DM).